The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

被引：58
|
作者：
Tzavara, ET [1 ]
Perry, KW [1 ]
Rodriguez, DE [1 ]
Bymaster, FP [1 ]
Nomikos, GG [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Neurosci Discovery Res, Indianapolis, IN 46285 USA
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2001年 / 426卷 / 03期
关键词：
microdialysis; norepinephrine; SR141716A;
D O I：
10.1016/S0014-2999(01)01228-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The effects of the selective cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide-hydrochloride (SR141716A) on extracellular concentrations of norepinephrine and 5-hydroxytryptamine (5-HT) were assessed by in vivo microdialysis in the anterior hypothalamus of freely moving rats. SR14716A (0.3, 1, 3 mg/kg, i.p.) dose-dependently increased norepinephrine efflux to about 300% of baseline, without affecting 5-HT levels. This increase in norepinephrine outflow could play an important role in the pharmacological and potentially therapeutic actions of SR141716A. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码：R3 / R4
页数：2
相关论文
共 50 条
  • [31] THE CB1 CANNABINOID RECEPTOR ANTAGONIST SR 141716A AFFECTS A(9) DOPAMINE NEURONAL-ACTIVITY IN THE RAT
    GUEUDET, C
    SANTUCCI, V
    RINALDICARMONA, M
    SOUBRIE, P
    LEFUR, G
    NEUROREPORT, 1995, 6 (10) : 1421 - 1425
  • [32] The CB1 receptor antagonist SR141716A inhibits Ca2+-induced relaxation in CB1 receptor deficient mice.: Possible role for a non-classial cannabinoid receptor?
    Bukoski, RD
    Batkai, S
    Jarai, Z
    Wang, YL
    Jackson, WF
    Kunos, G
    HYPERTENSION, 2001, 38 (03) : 509 - 509
  • [33] Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors
    MacLennan, SJ
    Reynen, PH
    Kwan, J
    Bonhaus, DW
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 : U96 - U96
  • [34] The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
    Tucci, SA
    Rogers, EK
    Korbonits, M
    Kirkham, TC
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) : 520 - 523
  • [35] The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats
    Serrano, Antonia
    del Arco, Ignacio
    Javier Pavon, Francisco
    Macias, Manuel
    Perez-Valero, Vidal
    Rodriguez de Fonseca, Fernando
    NEUROPHARMACOLOGY, 2008, 54 (01) : 226 - 234
  • [36] Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome
    Rubino, T
    Massi, P
    Viganò, D
    Fuzio, D
    Parolaro, D
    LIFE SCIENCES, 2000, 66 (22) : 2213 - 2219
  • [37] Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist
    Järbe, TUC
    Harris, MY
    Li, C
    Liu, Q
    Makriyannis, A
    PSYCHOPHARMACOLOGY, 2004, 177 (1-2) : 35 - 45
  • [38] Role of the cannabinoid CB1 receptor antagonist SR 141716A in relapse to heroin-seeking
    Fattore, L
    Spano, MS
    Deiana, S
    Cossu, G
    Melis, V
    Fadda, P
    Fratta, W
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S325 - S326
  • [39] SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset
    Simiand, J
    Keane, M
    Keane, PE
    Soubrié, P
    BEHAVIOURAL PHARMACOLOGY, 1998, 9 (02): : 179 - 181
  • [40] The CB1 receptor antagonist SR141716A heightens the development of tolerance to alcohol and modulates symptoms of dependence.
    Nowak, KL
    Yaragudri, V
    Hungund, BL
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2004, 28 (05) : 142A - 142A
12345